We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Fusion Pharmaceuticals Inc. Common Shares in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 112 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 114 → 0 (-114)

100% less funds holding in top 10

Funds holding in top 10: 8 → 0 (-8)

100% less capital invested

Capital invested by funds: $1.47B → $0 (-$1.47B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 112

Holders
–
Holders Change
-114
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
112
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
-$230M
2
PA
Perceptive Advisors
New York
-$146M
3
APM
Avidity Partners Management
Texas
-$139M
4
DM
Deerfield Management
New York
-$136M
5
Fidelity International
Fidelity International
Bermuda
-$89.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
– -$10.1M -473,376 Closed
SFM
27
Sphera Funds Management
Israel
– -$9.57M -449,041 Closed
Verition Fund Management
28
Verition Fund Management
Connecticut
– -$8.78M -412,034 Closed
DFO
29
Duquesne Family Office
New York
– -$8.52M -399,748 Closed
Two Sigma Investments
30
Two Sigma Investments
New York
– -$7.51M -352,485 Closed
Morgan Stanley
31
Morgan Stanley
New York
– -$6.35M -298,034 Closed
TI
32
Trexquant Investment
Connecticut
– -$6.05M -283,926 Closed
OAC
33
OMERS Administration Corp
Ontario, Canada
– -$5.89M -276,400 Closed
PFM
34
Privium Fund Management
Netherlands
– -$5.35M -251,158 Closed
SCM
35
Sio Capital Management
New York
– -$5.18M -243,035 Closed
ACM
36
Atika Capital Management
New York
– -$4.97M -233,000 Closed
ACM
37
ADAR1 Capital Management
Texas
– -$3.78M -177,200 Closed
CCM
38
Chicago Capital Management
Illinois
– -$3.63M -170,200 Closed
FAM
39
Fred Alger Management
New York
– -$3.57M -167,415 Closed
Hudson Bay Capital Management
40
Hudson Bay Capital Management
Connecticut
– -$3.52M -165,000 Closed
Axa
41
Axa
France
– -$3.51M -164,521 Closed
SI
42
Sofinnova Investments
California
– -$3.35M -157,172 Closed
MCP
43
Maso Capital Partners
Hong Kong
– -$3.2M -150,000 Closed
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
– -$3.15M -147,547 Closed
GF
45
Gabelli Funds
New York
– -$3.12M -146,150 Closed
HP
46
HealthInvest Partners
Sweden
– -$2.96M -138,836 Closed
HM
47
Harvest Management
New York
– -$2.56M -120,000 Closed
GCIA
48
Gabelli & Co Investment Advisers
New York
– -$2.47M -115,750 Closed
FTCM
49
First Trust Capital Management
Illinois
– -$2.3M -107,737 Closed
PCM
50
Prelude Capital Management
New York
– -$2.2M -103,298 Closed
1
2
3 4 5

FUSN Hedge Fund Activity: Q2 2024 in Review

0 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2024, worth a combined $0 — down 100% from $1.47B a quarter earlier.

Sellers outnumbered buyers: 112 funds closed out of FUSN and 0 opened new positions — a net loss of 112 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Federated Hermes, exiting entirely with an estimated $230M sold.

  • 0 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2024, down from 114 in Q1 2024.
  • Funds reported $0 of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2024 and 112 closed out, a net change of -112 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2024 was Federated Hermes, an estimated $230M sold.

Based on aggregated 13F filings for Q2 2024.